AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3303287
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg three times daily for 2 weeks
Trial: 3303287
Drug: Nicardipine 20-40
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20-40 mg three times daily during an open study in 30 patients
Trial: 30489620
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with remifentanil hydrochloride and propofol
Trial: 21593649
Drug: Orafti Synergy1
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orafti Synergy1 (50 oligofructose:50 FOS) 0.4 g/dL
Trial: 21593649
Drug: Orafti Synergy1
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orafti Synergy1 (50 oligofructose:50 FOS) 0.8 g/dL
Trial: 21593649
Drug: GOS:FOS (90:10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS:FOS (90:10) 0.8 g/dL
Trial: 12551829
Drug: Nadroparin (2,850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (2,850 IU subcutaneously daily for 90 days)
Trial: 12551829
Drug: Warfarin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (1 mg orally daily for 90 days)
Trial: 6638906
Drug: Metronidazole (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1000 mg vaginally preoperatively and 500 mg intravenously during surgery)
Trial: 22431675
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) (various doses)
Trial: 18240113
Drug: Schema-focused Emotive
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-focused Emotive Behavioural Therapy (SET)
Trial: 9456256
Drug: Daily filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily filgrastim (1 microg/kg daily, adjusted up to 10 microg/kg daily)
Trial: 9456256
Drug: Intermittent filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intermittent filgrastim (300 microg daily one to three times per week to a maximum of 600 microg daily)
Trial: 2404346
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 mg 3 times a day)
Trial: 713957
Drug: Biarison (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biarison (900 mg to 1500 mg/day)
Trial: 31067745
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 tablets (20,000 IU)
Trial: 27068367
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (self-administered action observation treatment)
Trial: 25449310
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at P6 point before chemotherapy infusion
Trial: 25449310
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg intravenously 30 min before chemotherapy infusion
Trial: 22952304
Drug: Constraint-induced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced therapy
Trial: 19190563
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL carbohydrate drink 2 hours before surgery
Trial: 17237664
Drug: Lacosamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (100 to 400 mg/d or maximum tolerated dose)
Trial: 11466696
Drug: Mylotarg (gemtuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylotarg (gemtuzumab ozogamicin) therapy
Trial: 9466172
Drug: Moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (450 mg/day, range 300-600 mg/day)
Trial: 9466172
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day, range 10-30 mg/day)
Trial: 7737072
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus 2 months use of the tape player
Trial: 226306
Drug: estradiol vaginal
RxNorm normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol vaginal cream
Trial: 226306
Drug: conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conjugated estrogen cream
Trial: 24628553
Drug: Pro+CHO (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro+CHO (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein with 60 g carbohydrate)
Trial: 24628553
Drug: Pro (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein without carbohydrate)
Trial: 22952178
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake of >500 mg · kg⁻¹ · d⁻¹
Trial: 22952178
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake of 500 mg · kg⁻¹ · d⁻¹
Trial: 22952178
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake of 750 mg · kg⁻¹ · d⁻¹
Trial: 18275575
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg orally 12 hourly for 24 hours
Trial: 18275575
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg orally 12 hourly for 24 hours
Trial: 15891564
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of therapy (3-6 months)
Trial: 12504699
Drug: Intacs microthin
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intacs microthin prescription inserts
Trial: 10800872
Drug: ZDV 100
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV 100 mg tid + 200 mg nocte (ZDV-A)
Trial: 10800872
Drug: ZDV 250
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV 250 mg bid (ZDV-B)
Trial: 8822458
Drug: MTX dissolved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX dissolved in saline solution (solution group)
Trial: 8822458
Drug: MTX suspensions
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX suspensions (suspension group)
Trial: 6986940
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of morphine sulphate (3.5 times the pain-relieving dose, mean 36 mg)
Trial: 6986940
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine sulphate (pain-relieving dose, mean 110 mg) administered four-hourly for the first 24 hours, six-hourly for the next 24 hours, and then eight and 20 hours later
Trial: 6986940
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine sulphate (pain-relieving dose, mean 140 mg) as required
Trial: 23800784
Drug: peg-interferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg-interferon α‐2a at 180 μg/week
Trial: 21297523
Drug: GH 33
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 33 μg/kg/d
Trial: 21297523
Drug: GH 67
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 67 μg/kg/d
Trial: 11158001
Drug: PTH infusion
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH infusion (0.55 U/kg.h for 24 h) before GnRH agonist therapy
Trial: 11158001
Drug: PTH infusion
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH infusion (0.55 U/kg.h for 24 h) after 6 months of GnRH agonist therapy
Trial: 11158001
Drug: PTH infusion
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH infusion (0.55 U/kg.h for 24 h)
Trial: 9663722
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg b.d.)
Trial: 9663722
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.)
Trial: 3223435
Drug: Ethanol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (doses ranging from 0 to 1.05 g/kg lean body weight)
Trial: 29343448
Drug: 300‐mg ropivacain/600‐300‐300‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg ropivacain/600‐300‐300‐mg gabapentin (Group A)
Trial: 29343448
Drug: 150‐mg ropivacain/600‐300‐300‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150‐mg ropivacain/600‐300‐300‐mg gabapentin (Group B)
Trial: 29343448
Drug: 300‐mg ropivacain/300‐100‐100‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg ropivacain/300‐100‐100‐mg gabapentin (Group C)
Trial: 29343448
Drug: 150‐mg ropivacain/300‐100‐100‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150‐mg ropivacain/300‐100‐100‐mg gabapentin (Group D)
Trial: 20627268
Drug: computerized cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computerized cognitive-behavioral therapy (cCBT)
Trial: 16964830
Drug: Amdoxovir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir (300 mg orally, twice daily)
Trial: 14576731
Drug: Sequential MRD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MRD monitoring post-ASCT
Trial: 10990114
Drug: Heparin-bonded central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded central venous lines (HB CVLs)
Trial: 10990114
Drug: Non-heparin-bonded central
RxNorm normalized name: SKIN BOND NON-FLAMMABLE CEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-bonded central venous lines (NHB CVLs)
Trial: 1550145
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin 333 mg every 8 hours from randomization to delivery
Trial: 3902238
Drug: mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (30 mg/day for the first week, then doubled for the next three weeks)
Trial: 3902238
Drug: maprotiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline (75 mg/day for the first week, then doubled for the next three weeks)
Trial: 27165240
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 30 mg/m2 and paclitaxel 35 mg/m2 for 5‐6 weeks along with radiotherapy
Trial: 15912390
Drug: 0.5% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% aqueous and 0.1% hydrogel formulations of timolol
Trial: 2550244
Drug: CGS 16617
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16617 50 mg/day
Trial: 2550244
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of CGS 16617 (20 to 100 mg)
Trial: 28859672
Drug: Laquinimod (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod (0.9 mg to 2.7 mg, escalating doses)
Trial: 26338490
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil application (twice-daily)
Trial: 23631607
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg three times a day)
Trial: 23631607
Drug: Nateglinide and
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide and Acarbose (both treatments)
Trial: 20723033
Drug: Edoxaban 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 5 mg
Trial: 25653574
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg
Trial: 20723033
Drug: All Edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Edoxaban doses
Trial: 19092465
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2%
Trial: 19092465
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol maleate 0.5%/dorzolamide 2%
Trial: 17017227
Drug: 5% suspension
RxNorm normalized name: Top Cat 4.5% Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% suspension concentrate beta‐cypermethrin (double dose 2S at 100 mg AI/m2)
Trial: 17017227
Drug: 5% suspension
RxNorm normalized name: Top Cat 4.5% Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% suspension concentrate beta‐cypermethrin (standard dose S at 50 mg AI/m2)
Trial: 17017227
Drug: 25% cypermethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% cypermethrin (CF at 100 mg AI/m2)
Trial: 17017227
Drug: 10% permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% permethrin (DF at 170 mg AI/m2)
Trial: 12818447
Drug: Tinidazole (T)
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole (T) 2g single dose + acidic vaginal gel (M) 2g every 3 days for 3 weeks
Trial: 6198368
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral and intravenous administration of kanamycin and metronidazole
Trial: 30699842
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination (S‐adenosyl methionine; Folinic acid; Omega‐3 fatty acids; 5‐HTP; Zinc picolinate)
Trial: 19383806
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dual-release hydrocortisone tablet
Trial: 19383806
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dual-release hydrocortisone tablet after a high-calorie, high-fat meal
Trial: 19383806
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dual-release hydrocortisone tablet
Trial: 10994544
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 14 mg/m2
Trial: 10994544
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 12 mg/m2
Trial: 10994544
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 30 mg/m2
Trial: 6563903
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 0.1 mg/kg in 15 ml of normal saline
Trial: 6563903
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 0.1 mg/kg and normal saline 15 ml epidurally
Trial: 6563903
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 15 ml epidurally and normal saline 0.01 ml/kg intramuscularly
Trial: 31930890
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy group (tongdu tiaoshen moxibustion + rehabilitation training)
Trial: 30123942
Drug: Risankizumab (0.01-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (0.01-5 mg/kg IV, 0.25-1 mg/kg SC, 18 mg SC, 90 mg SC, 180 mg SC for psoriasis; 200 or 600 mg IV every 4 weeks followed by 180 mg SC every 8 weeks for Crohn's disease)
Trial: 27487251
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine system (DMS) with wearable sensor
Trial: 22435769
Drug: Videoconferencing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing therapy
Trial: 17145205
Drug: Captopril 50mg
RxNorm normalized name: CAPTOPRIL 50MG TAB
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 50mg tablet
Trial: 12522748
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza virus vaccine with or without intranasal live‐attenuated, cold‐adapted influenza vaccine
Trial: 8844501
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections of inhalant allergens at the maximum intradermally tolerated dose (MITD)
Trial: 1477693
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol and alfentanil
Trial: 24421901
Drug: Tenofovir administered
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir administered 2 doses/week for 6 weeks
Trial: 24421901
Drug: Tenofovir administered
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir administered 4 doses/week for 6 weeks
Trial: 24421901
Drug: Tenofovir administered
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir administered 7 doses/week for 6 weeks
Trial: 16052841
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg twice/day
Trial: 10365650
Drug: Clozapine (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (200-400 mg/d) before and after Sodium Valproate (900-1200 mg/d) for 4 weeks (n = 6)
Trial: 1911013
Drug: Flumazenil 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.01 mg kg‐1
Trial: 6117682
Drug: Live influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live influenza vaccine
Trial: 6117682
Drug: Inactivated surface‐antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated surface‐antigen influenza vaccine
Trial: 28829884
Drug: Oral Prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone (20 mg tablets, 2 tablets once daily for 5 days)
Trial: 28829884
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched placebo, 2 tablets once daily for 5 days)
Trial: 22878231
Drug: tDCS (transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS (transcranial direct current stimulation) with cathodal stimulation, 20 minutes per day, 5 days per week, for 4 weeks, combined with conventional physical therapy
Trial: 22878231
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation combined with conventional physical therapy
Trial: 18163509
Drug: Infliximab every
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab every 6 weeks (continuous treatment)
Trial: 18163509
Drug: Infliximab upon
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab upon symptom recurrence (on-demand treatment)
Trial: 18163509
Drug: Infliximab alone
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab alone (on-demand treatment)
Trial: 18163509
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) in combination with infliximab (on-demand treatment)
Trial: 14501633
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen during the preoperative period
Trial: 8625627
Drug: 0.43 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.43 IU recombinant growth hormone/kg body weight/day for 12 days
Trial: 1425873
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied methylprednisolone aceponate (MPA) at the highest dose
Trial: 31530840
Drug: GB_a (acidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB_a (acidic gel base; 0 ppmF-, pH 4.75)
Trial: 31530840
Drug: GB_n (neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB_n (neutral gel base; 0 ppmF-, pH 7.0)
Trial: 31530840
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no gel, without/with pellicle)
Trial: 29753732
Drug: Extended-release nicotinic
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-release nicotinic acid for 8 weeks